BRCA2 and ovarian carcinoma: One important consideration is whether differentials in response to platinum-based chemotherapy between BRCA1- and BRCA2-mutated ovarian cancers observed in recent studies may also be true with respect to the therapeutic response elicited by PARP inhibitors.